In gastroenterology, as in other medical disciplines, treatment is dictated as much by current fashion as by fact, as much by the availability of new technology as by objective data. Willis in 1674 is credited with the first treatment of achalasia by dilatation. He used a whalebone dilator with great success, indeed with such prolonged success that the diagnosis in his patient must be in considerable doubt. Early this century, during the blossoming of abdominal surgery, Heller described the use of a double cardiomyotomy, modified subsequently by Zaijjer to the single myotomy used widely until recently. In parallel with this surgical experience, others preferred the use of balloon dilatation, using the Negus or Plummer bags and their variants.
With the advent of fibreoptic endoscopy, dilatation procedures have flourished, and several devices are marketed and used widely for balloon dilatation of the cardia. Because the majority of endoscopies are performed by physicians rather than surgeons, the treatment of achalasia has moved largely to the medical province. Indeed it is commonly accepted today that the first choice of treatment for achalasia is endoscopic balloon dilatation. It Both treatments give acceptable results, with a high proportion of patients obtaining almost complete relief from dysphagia. Reflux is uncommon after both treatments, but when it occurs it may cause severe problems, because of poor oesophageal contractility. Strictures in this disease are difficult to treat, the patient having exchanged a bad disease for a worse one. It is for this reason that surgeons, used to resolving these rare failures, often favour the addition of an antireflux procedure to a cardiomyotomy -an option not available at endoscopic dilatation.4
Ideally we should solve this debate by a randomised controlled clinical trial. Unfortunately, this is not easy in so rare a disease. Such controlled data do exist, however, in the study by Csendes et al, whose patients were randomised to have either balloon dilatation or a cardiomyotomy together with a form of antireflux procedure.5 Since the 1983 Editorial the data from this controlled trial have been extended. Treated with appropriate caution at that time because they were so recent, the passage of time has confirmed the superiority of the results of surgical treatment. At a median follow up of 62 months, excellent results were reported in 95% of patients after myotomy, but in only 65% after dilatation. The relief of dysphagia was greater, and more rapidly achieved in those treated surgically. In spite of the cardioplasty, however, reflux was greater in the surgical patients, although not severe in either.
On the whole these workers considered that myotomy was the preferred treatment based on their controlled data. Although some of the patients in this series had Chagas' disease, most had classical achalasia, and it is likely that the outcome would be similar in both diseases.
Surgical treatment has been bypassed by the majority because of its invasive nature, in spite of its possible advantages. In the era of minimally invasive surgery, the pendulum may now swing the other way. Both 
